Login / Signup
From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer.
Robert Pirker
Martin Filipits
Published in:
ESMO open (2019)
Keyphrases
</>
advanced non small cell lung cancer
combination therapy
replacement therapy